US Health Policy Proposes Cost-Cutting Overhaul

Brian Wang outlines a vision for US healthcare reforms advocating drug-price negotiation, AI-enabled care, and fraud crackdowns driven by Trump-era proposals and industry pledges. He cites most-favored-nation pricing demands, interoperability commitments from 600+ companies, GLP-1 price reductions (from about $1,200 to $200 monthly), and estimated Medicare/Medicaid fraud of 20–30%. The piece argues these measures could improve access, lower costs, and boost system efficiency.